KR20220097420A - 호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체 - Google Patents
호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체 Download PDFInfo
- Publication number
- KR20220097420A KR20220097420A KR1020227017188A KR20227017188A KR20220097420A KR 20220097420 A KR20220097420 A KR 20220097420A KR 1020227017188 A KR1020227017188 A KR 1020227017188A KR 20227017188 A KR20227017188 A KR 20227017188A KR 20220097420 A KR20220097420 A KR 20220097420A
- Authority
- KR
- South Korea
- Prior art keywords
- pyrazole
- phenyl
- oxo
- carboxamide
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1915273.5 | 2019-10-22 | ||
| GB201915273A GB201915273D0 (en) | 2019-10-22 | 2019-10-22 | Pharmaceutical compounds |
| PCT/GB2020/052658 WO2021079121A1 (en) | 2019-10-22 | 2020-10-22 | Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220097420A true KR20220097420A (ko) | 2022-07-07 |
Family
ID=68728299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227017188A Ceased KR20220097420A (ko) | 2019-10-22 | 2020-10-22 | 호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220409629A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4048665A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7667778B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220097420A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114761397B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158169A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201915273D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021079121A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202010409D0 (en) | 2020-07-07 | 2020-08-19 | Reviral Ltd | Pharmaceutical compounds |
| WO2024252355A1 (en) | 2023-06-08 | 2024-12-12 | Pfizer Inc. | Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv |
| WO2025120500A1 (en) | 2023-12-06 | 2025-06-12 | Pfizer Inc. | Benzodiazepine compounds as n-protein inhibitors |
| CN122580320A (zh) | 2024-01-16 | 2026-08-14 | 辉瑞大药厂 | 作为n-蛋白抑制剂的苯二氮䓬吡唑甲酰胺类 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314595A (pt) * | 2002-09-20 | 2005-08-09 | Arrow Therapeutics Ltd | Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica |
| GB0221923D0 (en) * | 2002-09-20 | 2002-10-30 | Arrow Therapeutics Ltd | Chemical compounds |
| GB0406280D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Chemical compounds |
| GB0406282D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| US20070293482A1 (en) * | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
| GB0406279D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| CA2622592A1 (en) * | 2005-09-19 | 2007-03-29 | Arrow Therapeutics Limited | Benzodiazepine derivatives for treating hepatitis c infection |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| GB201506448D0 (en) | 2015-04-16 | 2015-06-03 | Univ Durham | An antimicrobial compound |
| MY197231A (en) * | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| GB201613942D0 (en) | 2016-08-15 | 2016-09-28 | Univ Of Durham The | An antimicrobial compound |
| WO2018129287A1 (en) | 2017-01-06 | 2018-07-12 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as rsv inhibitors |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| WO2020190935A1 (en) * | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| GB201911944D0 (en) * | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
-
2019
- 2019-10-22 GB GB201915273A patent/GB201915273D0/en not_active Ceased
-
2020
- 2020-10-22 KR KR1020227017188A patent/KR20220097420A/ko not_active Ceased
- 2020-10-22 EP EP20800253.5A patent/EP4048665A1/en not_active Withdrawn
- 2020-10-22 US US17/770,455 patent/US20220409629A1/en not_active Abandoned
- 2020-10-22 CN CN202080082952.6A patent/CN114761397B/zh active Active
- 2020-10-22 JP JP2022523558A patent/JP7667778B2/ja active Active
- 2020-10-22 CA CA3158169A patent/CA3158169A1/en active Pending
- 2020-10-22 WO PCT/GB2020/052658 patent/WO2021079121A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021079121A1 (en) | 2021-04-29 |
| CN114761397B (zh) | 2024-11-05 |
| US20220409629A1 (en) | 2022-12-29 |
| GB201915273D0 (en) | 2019-12-04 |
| CN114761397A (zh) | 2022-07-15 |
| CA3158169A1 (en) | 2021-04-29 |
| JP7667778B2 (ja) | 2025-04-23 |
| JP2022553700A (ja) | 2022-12-26 |
| EP4048665A1 (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7667778B2 (ja) | 呼吸器合胞体ウイルス(rsv)感染症を治療するためのベンゾジアゼピン誘導体 | |
| DK2978752T3 (en) | 6- (5-HYDROXY-1H-PYRAZOL-1-YL) NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | |
| JP7667779B2 (ja) | 医薬化合物 | |
| JP2020019812A (ja) | Lsd1阻害剤としてのシクロプロピルアミン類 | |
| KR20220075317A (ko) | 약학적 화합물 | |
| JP6695334B2 (ja) | 呼吸器合胞体ウイルス感染症(rsv)の治療又は予防のためのスピロインドリン | |
| JP2023539985A (ja) | 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体 | |
| WO2022008912A1 (en) | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection | |
| US11078189B2 (en) | Pharmaceutical compounds | |
| ES2905650T3 (es) | Compuestos farmacéuticos | |
| WO2022180397A1 (en) | Benzodiazepines for treating or preventing respiratory syncytial virus infection | |
| CN105899504A (zh) | 用于治疗和预防呼吸道合胞病毒感染的咪唑化合物 | |
| KR102873079B1 (ko) | Rna 바이러스 감염 치료를 위한 아릴-n-아릴 유도체 | |
| CA3273670A1 (en) | Inhibitors of .alpha.-hemolysin of staphylococcus aureus | |
| HK1217701B (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| HK1228383A1 (en) | Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |